Cellceutix Corp (CTIX) 3.8500 $CTIX Ulcerative Colitis

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Cellceutix Corp (CTIX) 3.8500 $CTIX

Ulcerative Colitis Therapeutics Pipeline Review 2015 - 66 Companies & 99 Drug Profiles
M2 - Tue Mar 03, 6:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/kwqzpf/ulcerative) has announced the addition of the "Ulcerative Colitis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ulcerative Colitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ulcerative Colitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Ajinomoto Pharmaceuticals Co., Ltd. - AlphaMab Co., Ltd - Altheus Therapeutics, Inc. - Am-Pharma B.V. - Amgen Inc. - Astellas Pharma Inc. - AstraZeneca PLC - Athersys, Inc. - Atlantic Healthcare plc - Avaxia Biologics, Inc. - Biocon Limited - BioLineRx, Ltd. - Bristol-Myers Squibb Company - Celgene Corporation - Cellceutix Corporation - Celltrion, Inc. - ChemoCentryx, Inc. - ChironWells GmbH - Cosmo Pharmaceuticals S.p.A - Dr. Falk Pharma GmbH - Drais Pharmaceuticals, Inc. - Effimune SAS - Emergent BioSolutions Inc. - Enceladus Pharmaceuticals BV - Epirus Biopharmaceuticals, Inc. - Euroscreen S.A. - Farmacija d.o.o. Tuzla - Flexion Therapeutics, Inc. - Galapagos NV - Genentech, Inc. For more information visit http://www.researchandmarkets.com/research/kwqzpf/ulcerative
FLXN: 24.11 (-1.16), EBS: 28.42 (-0.82), AMGN: 154.88 (-4.72), BMY: 65.12 (-0.93), AZN: 66.27 (-1.91), CCXI: 7.74 (-0.24), ATHX: 2.98 (+0.10), CELGZ: 3.21 (unch)

Cellceutix to Expand Its Skin Product Pipeline
Marketwired - Mon Mar 02, 8:32AM CST
Cellceutix Corporation (OTC: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, and antimicrobial applications, is pleased to announce that it is expanding its dermatology pipeline to include novel Human Defense Protein (HDP) mimetics for the treatment of chronic skin conditions, such as acne vulgaris, rosacea, and hidradenitis suppurativa (HS). Recently conducted pre-clinical research supports these conditions as targets due to the robust antimicrobial and anti-inflammatory properties of Cellceutix's HDP mimetics. These are conditions for which there is no consistently effective treatment, as in the case of HS, or there is room to improve upon current therapies, as in acne vulgaris or rosacea. In these conditions, topical antibiotics have been used, with mixed or disappointing results, most likely due to a lack of anti-inflammatory activity in concert with an inability to treat bacteria, such as Propionibacterium acnes, that are growing increasingly resistant to current therapies. The HDP mimetics can overcome both hurdles: they have anti-inflammatory properties and they can kill key bacteria without promoting further resistance. The latter is important, because traditional antibiotics, when chronically used, are likely to promote resistance, whereas HDP mimetics, given their unique structure and mechanism of action, are unlikely to promote resistance.

Seeking Alpha's Biotech Weekly: Crush-Proof Pfizer, Achillion's HCV Crusher, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 13, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
VRX: 198.71 (-5.24), ACT: 289.92 (-5.78), MDT: 76.48 (-2.02), XON: 50.16 (+0.66), CTIC: 2.65 (-0.07), PFNX: 14.38 (+0.35), JNJ: 100.11 (-2.41), ANTM: 145.16 (-1.69), NVAX: 8.80 (-0.14), SHPG: 235.75 (-2.31), ABBV: 55.64 (-1.22), TBPH: 20.23 (-0.52), SNY: 47.42 (-0.94), ALQA: 5.29 (-0.07), REGN: 422.13 (-6.82), ONCY: 0.90 (-0.15), PFE: 33.97 (-0.50), SLXP: 158.01 (+0.57), EPRS: 11.35 (-0.12), AMGN: 154.88 (-4.72), NKTR: 13.02 (-0.28), ZTS: 45.78 (-0.68), GILD: 101.81 (-1.61), ACHN: 11.39 (+0.40), GERN: 3.50 (-0.28)

IHUB Most Posted And Most Read Stocks Do Not Perform Well
Anthony Cataldo - at Seeking Alpha - Wed Feb 11, 8:43AM CST

PPHM: 1.63 (+0.06)

An Interview With Cellceutix CEO Leo Ehrlich
KarinCA - at Seeking Alpha - Mon Feb 09, 9:31AM CST

MRK: 56.84 (-1.14)

Cellceutix: Why An Uplisting Is Not Possible Right Now
Bleecker Street Research - at Seeking Alpha - Fri Feb 06, 1:26PM CST


$CTIX - Cellceutix Undervalued By 90+%; Expect A Short Squeeze Soon
KarinCA - at Seeking Alpha - Thu Jan 29, 3:13PM CST

JNJ: 100.11 (-2.41), CBSTZ: 0.06 (unch), ACT: 289.92 (-5.78), PFE: 33.97 (-0.50), MRK: 56.84 (-1.14), AMGN: 154.88 (-4.72), LLY: 68.41 (-2.18), ABBV: 55.64 (-1.22), NVS: 97.46 (-1.49)

Cellceutix Plans Clinical Trial in Patients With Ulcerative Proctitis
Marketwired - Mon Jan 26, 6:00AM CST
Cellceutix Corporation (OTC: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology and antimicrobial applications, is pleased to announce that it is submitting a request early this week to the Food and Drug Administration (FDA) Division of Gastroenterology and Inborn Errors Products to conduct a pre-Investigational New Drug (IND) meeting to discuss development of a topical defensin-mimetic compound for the indication of induction of remission of ulcerative proctitis and ulcerative proctosigmoiditis.

Cellceutix: A December To Remember May Turn Into A 2015 To Forget For CTIX
Bleecker Street Research - at Seeking Alpha - Fri Jan 23, 9:30AM CST


Autism Therapeutic Pipeline Drugs and Companies Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Fri Jan 23, 6:36AM CST
The report "Autism - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Autism. Autism is known as a multifarious developmental disability. Autism disorder is characterized by social activities, non-verbal communication and repetitive behavior. Autism is highly transmissible but the cause includes both environmental factors and genetic susceptibility. It has long been assumed that there is a common cause at the genetic, cognitive and neural levels for autism's characteristic triad of symptoms. The report enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Complete Report is Available @ http://www.rnrmarketresearch.com/autism-pipel...eport.html .
TEVA: 56.40 (-0.11), ITCI: 23.80 (-0.93), BCLI: 4.39 (+0.02), OMER: 26.14 (-0.21), NVS: 97.46 (-1.49)

Will Cannabis Be The Biggest Thing In Biotech For 2015?
ACCESSWIRE - Thu Jan 22, 8:13AM CST
CORAL GABLES, FL / ACCESSWIRE / January 22, 2015 / Attention on marijuana stocks has increased since Colorado legalized it for recreational use in 2014. With larger institutional investment flowing into the industry, there's no doubt that this may be just the beginning for stocks in this sector. With 2016 slated as the next vote for more states to come online for legalization of medical and recreational licensing, much speculation has given rise to where to invest as it would appear not many new developments may come about until more states can come online. Biotech has been one of the identified target markets as regulation does not limit these organizations to particular state laws but more on the Federal side, specifically the FDA. From prescription sprays to cannabinoid oils, the biotech space may offer potential investment opportunity prior to the next vote.

Cellceutix Phase 2b Clinical Trial of Brilacidin Accepted for Oral Presentation at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
Marketwired - Thu Jan 22, 6:00AM CST
Cellceutix Corporation (OTC: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology and antimicrobial applications, is pleased to report that results of its recently completed phase 2b clinical trial "A Randomized, Double-Blind Study Comparing Single-Dose and Short-Course Brilacidin to Daptomycin in the Treatment of Acute Bacterial Skin & Skin Structure Infections (ABSSSI)" will be given in an oral presentation at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) to be held in Copenhagen, Denmark from April 25-28, 2015. ECCMID is one of the largest annual gatherings of infectious disease experts in the world, and an ideal forum to present the results of a clinical trial. Dr. Daniel Jorgensen, Cellceutix's Chief Medical Officer, will give the presentation during a session entitled "New Antibacterial Agents - Phase 2 and Phase 3 Clinical Trials."

Cellceutix up on report of positive results in clinical trial
Seeking Alpha - at Seeking Alpha - Tue Jan 20, 12:11PM CST


Cellceutix Reports Spleen Lesion 'Disappears' in Patient With Metastatic Stage 4 Ovarian Cancer in Clinical Trial of Anti-Cancer Drug Kevetrin
Marketwired - Tue Jan 20, 6:01AM CST
Cellceutix Corporation (OTC: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology and antimicrobial applications, is pleased to report the near complete disappearance of a metastatic lesion in the spleen of a Stage 4 ovarian cancer patient who was enrolled in the Company's Phase 1 clinical trial of anti-cancer drug candidate Kevetrin(TM) being conducted at Harvard Cancer Center's Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center. According to information supplied by the hospital, the patient, who successfully completed three Kevetrin 3-dose cycles before discontinuing the trial, experienced increased energy, while scans showed a reduction in the amount of peritoneal fluid (ascites) during treatment with Kevetrin. Subsequent to the second and third Kevetrin cycles, scans showed the spleen lesion to be essentially undetectable and the patient's disease to be clinically stable.

Cellceutix Invites All to Attend Company's Live Webcast of Presentation at Biotech Showcase 2015 Today at 2:00 PM PT (5:00 PM ET)
Marketwired - Mon Jan 12, 6:01AM CST
Cellceutix Corporation (OTCBB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology and antimicrobial applications, invites all interested parties to join the Company during its live webcast presentation at Biotech Showcase 2015 today, Monday, January 12 at 2:00 PM PT (5:00 PM ET). The conference is being held at Parc 55 Wyndham San Francisco (Union Square) in San Francisco, CA on January 12-14, 2015. Cellceutix will be presenting in Room Powell.

Cellceutix Overvalued By 90-99%
Ben Sharvy - at Seeking Alpha - Fri Jan 02, 4:21PM CST

VNDA: 10.47 (-0.24), VTAE: 10.87 (-0.29), XNCR: 15.33 (-0.67)

OTC Daily Alert Stock Watch - Cellceutix (OTC: CTIX)
WorldStockWire - Mon Dec 29, 3:15PM CST
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com

New medical chief at Cellceutix
Seeking Alpha - at Seeking Alpha - Mon Dec 29, 6:28AM CST


Cellceutix Adds Dr. Daniel Jorgensen as Chief Medical Officer
Marketwired - Mon Dec 29, 6:00AM CST
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology and antimicrobial applications, is pleased to announce that Daniel Jorgenson MD, MPH, MBA will join the Cellceutix team as Chief Medical Officer as of January 1, 2015.

CorMedix Update: Setting A New Standard For Catheter Care
Mark Kroenke - Seeking Alpha - Sun Dec 28, 6:07AM CST
Back in August, CorMedix (NYSEMKT: CRMD ) had a long to do list. In the last 4 months, the company has delivered on many promises: An IND for the pivotal Neutrolin study in the US was filed and accepted. The EU Neutrolin label was successfully...
CRMD: 8.25 (+0.49)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ontario Airport Braces for Holiday Travel Surge

Updated Category News Views 92

Gearing Up for a Thanksgiving Travel Boom Think Thanksgiving brings only turkey to the table? Down in Ontario, California, it's all about jet fuel and passenger counts. The Ontario International Airport (ONT) is where the skies are buzzing, forecasting over 227,000 passengers trying to soak up the holiday vibes by air. Compare that to the numbers when the local folks...

Continue Reading
LinkedIn Shines: Brands Face Social Media Slump

Updated Category News Views 71

LinkedIn: The Unsung Hero in Social Platforms In a world where social media seems to be as unpredictable as the stock market, LinkedIn is surprisingly holding the line. According to Vista Social's 2027 report, LinkedIn proudly boasts the highest median engagement rate among brand pages at 5.8%. Now, in the wild west of social media, where reach is getting tougher to snag,...

Continue Reading
First Time Homebuyer Tips for Southern Maryland Success

Updated Category News Views 54

Shaking Up First-Time Homebuyer Assumptions Ever hear that age-old nonsense about needing a fat stack of cash as a down payment before you can snag your first home? Yeah, turns out that's about as outdated as a rotary phone. Robin Cavallaro from RE/MAX Realty Group in Annapolis is setting the record straight for first-time buyers in Southern Maryland. Down Payment Myths...

Continue Reading
HLTH USA 2026 Spotlights AI and Health Innovation

Updated Category News Views 77

The Pulse of Innovation at HLTH USA 2026 Diving headfirst into the heart of healthcare innovation, HLTH USA 2026 kicked off with gusto in Las Vegas. Discussions are swirling around AI advancements and the next generation of payer-provider collaboration. Who knew healthcare could be this thrilling? The event is already shaping up to be a powerhouse of change, buzzing with...

Continue Reading
Bacterial Breakthrough in Cancer Therapy: Game Changer?

Updated Category News Views 60

Blurring Lines Between Bugs and Biotech Well, wouldn't you know it, the eggheads over at Jeonbuk National University in South Korea are at it again, pushing the boundaries of what these little bacterial buggers can do. This time, they’ve had a crack at cancer therapy, using engineered Salmonella to pack a double punch against breast cancer in mice. Now, if that ain't...

Continue Reading
Tigo Energy Faces Lawsuit: Key Details for Investors

Updated Category News Views 89

Tigo Energy Inc.'s Troubles: A Stock Drop and Legal Woes You see, not every day do you wake up to find your investment taking a nose dive by 36.76%. But that’s exactly what happened to Tigo Energy, Inc. (NASDAQ: TYGO) after some shaky announcements. A Rollercoaster for Investors On August 4, 2026, Tigo hit investors with a one-two punch: revised financial outlook and...

Continue Reading
Rock Tech Uncovers Major Lithium Discovery at Victory

Updated Category News Views 84

Rock Tech's Game-Changer at Victory Folks, we've got a shake-up in the lithium landscape over in Ontario, courtesy of Rock Tech Lithium Inc. They just unearthed something quite promising at their Victory Project: a spanking new spodumene-bearing pegmatite discovery. Now I know, if you're like me, you're thinking, 'What's the angle here?' Well, this isn't just another hole...

Continue Reading
Pine Tree Bets Big on Tulsa Hills Shopping Center

Updated Category News Views 152

Pine Tree's Latest Move in Retail Real Estate Ya ever watch a company make a move so aligned with its playbook that it feels like a script straight outta the boardroom? That's Pine Tree with its recent snag of Tulsa Hills Shopping Center for a cool $108 million. This ain't just any retail spot; it's a bustling hub nestled within the posh outskirts of Jenks, Oklahoma....

Continue Reading
Kansai Powers Up US Grid with Bold Investment Move

Updated Category News Views 99

Betting Big on Battery Storage Let's unpack this big move by Kansai Electric. Anytime a major player like Kansai steps out of its home turf, folks better pay attention. Looks like Kansai's gotten cozy with Elevate and ArcLight, nabbing a minority stake in Prospect Power. This ain't your average widget factory—it's a beefy 150MW/600MWh battery energy storage facility in...

Continue Reading
Segway Powersports Dominates Baja 1000 with Class 2 Sweep

Updated Category News Views 109

Catching the eye of any betting man, Segway Powersports has turned its maiden outing at the relentless SCORE Baja 1000 into a rousing victory. Their arrival on this unforgiving stage with a one-two in Class 2 isn't just a lucky roll—you don't chance upon podium sweeps in such gritty contests. Dissecting the Drive: Commitment and Coordination Unfolding across Baja's...

Continue Reading

Top 5 Most Recently Viewed Articles

Algeness® VL Filler Receives Marketing Approval in China

Updated Category News Views 273

Exciting Developments for Advanced Aesthetic Technologies Advanced Aesthetic Technologies, Inc. (AAT) recently celebrated a significant milestone with the approval of their Algeness® VL agarose facial injection filler for marketing in China. This landmark achievement opens up new avenues for AAT in expanding their product offerings in the Asian market and showcases their...

Continue Reading
Criminal Charges Anticipated in Trump Campaign Hacking Case

Updated Category News Views 154

Criminal Charges Expected in Trump Campaign Hacking Case U.S. authorities are preparing to file criminal charges regarding an incident in which the Trump campaign claimed its internal communications were hacked, allegedly by the Iranian government. This concerning situation has drawn the attention of both the public and officials, raising serious issues surrounding...

Continue Reading
Semler Scientific Faces Class Action Lawsuit: What Investors Need to Know

Updated Category News Views 187

Semler Scientific and the Class Action Lawsuit Overview In recent news, a class action lawsuit has taken center stage involving Semler Scientific, Inc. (SMLR). Investors who have experienced losses related to their investments in Semler are advised to take note of this development, which may directly impact their financial outcomes. Understanding the Lawsuit This class...

Continue Reading
FTC Solar Engages Investors at Key Industry Conferences

Updated Category News Views 159

FTC Solar Engages Investors at Key Industry Conferences FTC Solar, Inc. (Nasdaq: FTCI), an innovative leader in solar tracker systems and engineering services, is set to make significant strides in connecting with investors at three prominent conferences. These events provide a platform for the management team, including CEO Yann Brandt, to engage in discussions that...

Continue Reading
Anixa Biosciences Set to Share Innovations in Cancer Therapy

Updated Category News Views 88

Anixa Biosciences Set to Conduct a Notable Presentation Anixa Biosciences, Inc. (NASDAQ: ANIX), a leading biotechnology firm dedicated to the treatment and prevention of cancer, has taken a significant step forward by announcing its participation in a prestigious investment conference. This event, the H.C. Wainwright 27th Annual Global Investment Conference, promises to...

Continue Reading